In the US, incidence of primary myelofibrosis (PMF) is reported to be 0.44 per 100,000 person-years (data from 2002 to 2016).[4]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
In the UK, annual incidence of PMF is estimated to be 0.6 per 100,000, with an estimated 380 people newly diagnosed each year (data from 2010 to 2019).[5]HMRN. Factsheets [internet publication].
https://hmrn.org/factsheets
In Europe, incidence is reported to be between 0.1 to 1 per 100,000 persons per year.[6]Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014 Apr;92(4):289-97.
http://www.ncbi.nlm.nih.gov/pubmed/24372927?tool=bestpractice.com
PMF occurs more commonly in males (male to female rate ratio approximately 1.8 in the US, and 1.6 in the UK).[4]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
[5]HMRN. Factsheets [internet publication].
https://hmrn.org/factsheets
Incidence in the US is reported to be highest among white people.[4]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
PMF more commonly affects older people (approximately 66% of patients in the US are age ≥65 years at diagnosis), but younger people may develop the disease.[4]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
Median age at diagnosis is 70 years in the US, and 73 years in the UK.[4]Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Mar;63(3):694-702.
https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1992756
http://www.ncbi.nlm.nih.gov/pubmed/34689695?tool=bestpractice.com
[5]HMRN. Factsheets [internet publication].
https://hmrn.org/factsheets